Discovery Laboratories (DSCO) 1.43 $DSCO
5 Stocks Ready for Breakouts: Qiwi, RadNet and More
at The Street - Fri Feb 06, 9:03AM CST
These stocks are poised to break out and trade higher from current levels.
QIWI: 25.16 (+1.45), RDNT: 8.66 (-0.11), TPLM: 5.68 (+0.06), DWCH: 6.26 (-0.18), DSCO: 1.43 (+0.05)
Discovery Laboratories Latest Stock Surge Intriguing
AlphaIdeas - at Seeking Alpha - Wed Jan 14, 3:33PM CST
DSCO: 1.43 (+0.05)
Discovery Laboratories (DSCO) Jumps: Stock Rises 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 7:51AM CST
Discovery Laboratories Inc. (DSCO) was a big mover last session, as its shares rose almost 7% on the day.
AMAG: 41.49 (+0.23), DSCO: 1.43 (+0.05)
Discovery Laboratories Up 8.2%, Shares Break Through Resistance (DSCO)
Comtex SmarTrend(R) - Tue Jan 13, 1:30AM CST
Discovery Laboratories (NASDAQ
SCO) is one of today's best performing low-priced stocks, up 8.2% to $1.45 on 1.1x average daily volume. Discovery Laboratories has traded 449,000 shares thus far today, vs. average volume of 424,000 shares per day. The stock has outperformed the Dow (8.2% to the Dow's -0.4%) and outperformed the S&P 500 (8.2% to the S&P's -0.6%) during today's trading.
DSCO: 1.43 (+0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), ABCO: 53.69 (+0.32), ZAZA: 2.17 (+0.08), JMEI: 12.67 (+0.31), SGMO: 15.40 (+0.14), TGTX: 13.13 (-0.19), MEI: 39.40 (+0.22), WLT: 1.09 (+0.05), NSPR: 0.70 (-0.05), VII: 1.47 (-0.02), CVTI: 29.64 (-0.13), MEIP: 5.00 (-0.04), ALDR: 26.06 (+0.18), CALA: 16.11 (+0.62), CGG: 6.86 (+0.06), SPP: 1.36 (unch), DSCO: 1.43 (+0.05), KPTI: 27.12 (-0.13), HBOS: 24.84 (+0.14)
Investors look to Lighten Up on Shares of Discovery Laboratories, Shares Down 5.0% (DSCO)
Comtex SmarTrend(R) - Tue Dec 09, 10:37AM CST
Discovery Laboratories (NASDAQ SCO) is one of today's worst performing low-priced stocks, down 5.0% to $1.14 on 1.2x average daily volume. Discovery Laboratories has traded 275,000 shares thus far today, vs. average volume of 224,000 shares per day. The stock has underperformed the Dow (-5.0% to the Dow's -0.9%) and underperformed the S&P 500 (-5.0% to the S&P's -0.8%) during today's trading.
DSCO: 1.43 (+0.05)
Discovery Labs Partners with March of Dimes on 2015 Prematurity Awareness Campaign
PR Newswire - Wed Nov 19, 8:00AM CST
In recognition of Prematurity Awareness Month, Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care with an initial focus on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants, today announced that they are a March of Dimes' southeast Pennsylvania partner for their 2015 Prematurity Awareness Campaign. The program is designed to raise awareness of the urgency of the public health crisis of preterm birth and the ramifications of prematurity on infants and their families, and to thank healthcare professionals in neonatal intensive care units for their great efforts in caring for premature infants. Through this partnership, March of Dimes and Discovery Labs will share educational pieces for women of child bearing age in the five-county Philadelphia area to help educate mothers-to-be on prematurity and to foster awareness to help families have full-term, healthy babies.
DSCO: 1.43 (+0.05)
Discovery Laboratories' (DSCO) CEO John Cooper on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 10:12AM CST
DSCO: 1.43 (+0.05)
Discovery Laboratories posts 3Q loss
Automated Insights - Thu Nov 06, 9:12AM CST
WARRINGTON, Pa. (AP) _ Discovery Laboratories Inc. (DSCO) on Thursday reported a loss of $11.3 million in its third quarter.
DSCO: 1.43 (+0.05)
Discovery Laboratories beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:39AM CST
DSCO: 1.43 (+0.05)
Discovery Labs Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 6:30AM CST
Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the third quarter ended September 30, 2014, as well as recent business updates. The Company will host a conference call today, November 6, 2014 at 9:00 AM ET to discuss the 2014 third quarter financial results and other business updates.
DSCO: 1.43 (+0.05)
Discovery Labs Announces Organizational Change and Enhanced Expertise in Neonatology
PR Newswire - Thu Oct 30, 3:51PM CDT
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced organizational changes to the development leadership team and a special advisory appointment to augment the company's expertise in neonatology and aerosolized drug delivery.
DSCO: 1.43 (+0.05)
Discovery Labs to Report 2014 Third Quarter Financial Results and Hold Conference Call on Thursday, November 6, 2014 at 9:00 a.m. Eastern Time
PR Newswire - Wed Oct 29, 6:30AM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, will report its third quarter 2014 financial results on November 6, 2014 before the open of the U.S. financial markets.
DSCO: 1.43 (+0.05)
Discovery Laboratories: Collaboration With Battelle Is Validation Of Aerosurf's Potential By A Sophisticated Third Party
Smith On Stocks - at Seeking Alpha - Fri Oct 17, 7:16AM CDT
MNKD: 7.00 (+0.02), DSCO: 1.43 (+0.05)
Discovery Labs Announces Strategic Collaboration With Battelle For AEROSURF® Program
PR Newswire - Wed Oct 15, 6:30AM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it has entered into a strategic collaboration with Battelle, the world's largest independent research and development organization with 35 years of specific expertise in aerosol science. The parties intend to further develop Discovery Labs' proprietary capillary aerosol generator (CAG) for use in the planned AEROSURF® phase 3 clinical program and, if approved, initial commercialization. The arrangement also reflects the plan to negotiate agreements to provide for the manufacture of phase 3 clinical devices and, if AEROSURF is approved, initial commercial supply. The CAG is currently being used in neonatal intensive care units for the company's AEROSURF phase 2 clinical program for the treatment of respiratory distress syndrome (RDS) in premature infants. Battelle and Discovery Labs generally will share equally in the agreed costs of the device development for the AEROSURF RDS program. In consideration for its investment and expertise, Battelle will receive warrants and future royalties on AEROSURF sales and license sales revenues.
DSCO: 1.43 (+0.05)
Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury
PR Newswire - Wed Oct 01, 7:00AM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that the Company has been awarded a Phase II Small Business Innovation Research Grant (SBIR) valued at up to $3.0 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of the Company's aerosolized KL4 surfactant as a medical countermeasure to mitigate acute and chronic/late-phase radiation-induced lung injury. The company has been awarded $1.0 million, and over the next three years may be awarded up to an additional $2.0 million as part of this grant. This program will be conducted in conjunction with Melpo Christofidou-Solomidou, Ph.D., a leading expert in novel antioxidant approaches to acute and chronic lung diseases from the University of Pennsylvania's Perelman School of Medicine. In fiscal year 2010, the Perelman School of Medicine received $583 million in support for its research activities from extramural sponsors, including $408 million from the National Institutes of Health, ranking third in the nation among all academic medical institutions.
DSCO: 1.43 (+0.05)
Your September Biotech Back-to-School Calendar
at The Street - Tue Aug 26, 8:50AM CDT
The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year.
OREX: 5.55 (+0.10), GILD: 101.90 (+1.10), CPRX: 3.36 (-0.10), ALIM: 5.16 (unch), AMRN: 1.18 (unch), ADHD: 6.92 (+0.73), SNSS: 2.28 (+0.01), NPSP: 45.88 (+0.03), LPCN: 5.91 (+0.40), DSCO: 1.43 (+0.05), XOMA: 3.41 (-0.01), KERX: 11.63 (-0.60)
Discovery Laboratories (DSCO) Worth Watching: Stock Up 6.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:25AM CDT
Discovery Laboratories (DSCO) was a big mover last session, with shares rising nearly 7% on the day.
HSKA: 20.95 (+0.07), GILD: 101.90 (+1.10), ILMN: 198.54 (+1.81), DSCO: 1.43 (+0.05)
5 Stocks Ready for Breakouts: Qiwi, RadNet and More
at The Street - Fri Feb 06, 9:03AM CST
These stocks are poised to break out and trade higher from current levels.
QIWI: 25.16 (+1.45), RDNT: 8.66 (-0.11), TPLM: 5.68 (+0.06), DWCH: 6.26 (-0.18), DSCO: 1.43 (+0.05)
Discovery Laboratories Latest Stock Surge Intriguing
AlphaIdeas - at Seeking Alpha - Wed Jan 14, 3:33PM CST
DSCO: 1.43 (+0.05)
Discovery Laboratories (DSCO) Jumps: Stock Rises 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 7:51AM CST
Discovery Laboratories Inc. (DSCO) was a big mover last session, as its shares rose almost 7% on the day.
AMAG: 41.49 (+0.23), DSCO: 1.43 (+0.05)
Discovery Laboratories Up 8.2%, Shares Break Through Resistance (DSCO)
Comtex SmarTrend(R) - Tue Jan 13, 1:30AM CST
Discovery Laboratories (NASDAQ
SCO) is one of today's best performing low-priced stocks, up 8.2% to $1.45 on 1.1x average daily volume. Discovery Laboratories has traded 449,000 shares thus far today, vs. average volume of 424,000 shares per day. The stock has outperformed the Dow (8.2% to the Dow's -0.4%) and outperformed the S&P 500 (8.2% to the S&P's -0.6%) during today's trading. DSCO: 1.43 (+0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), ABCO: 53.69 (+0.32), ZAZA: 2.17 (+0.08), JMEI: 12.67 (+0.31), SGMO: 15.40 (+0.14), TGTX: 13.13 (-0.19), MEI: 39.40 (+0.22), WLT: 1.09 (+0.05), NSPR: 0.70 (-0.05), VII: 1.47 (-0.02), CVTI: 29.64 (-0.13), MEIP: 5.00 (-0.04), ALDR: 26.06 (+0.18), CALA: 16.11 (+0.62), CGG: 6.86 (+0.06), SPP: 1.36 (unch), DSCO: 1.43 (+0.05), KPTI: 27.12 (-0.13), HBOS: 24.84 (+0.14)
Investors look to Lighten Up on Shares of Discovery Laboratories, Shares Down 5.0% (DSCO)
Comtex SmarTrend(R) - Tue Dec 09, 10:37AM CST
Discovery Laboratories (NASDAQ
SCO) is one of today's worst performing low-priced stocks, down 5.0% to $1.14 on 1.2x average daily volume. Discovery Laboratories has traded 275,000 shares thus far today, vs. average volume of 224,000 shares per day. The stock has underperformed the Dow (-5.0% to the Dow's -0.9%) and underperformed the S&P 500 (-5.0% to the S&P's -0.8%) during today's trading. DSCO: 1.43 (+0.05)
Discovery Labs Partners with March of Dimes on 2015 Prematurity Awareness Campaign
PR Newswire - Wed Nov 19, 8:00AM CST
In recognition of Prematurity Awareness Month, Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care with an initial focus on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants, today announced that they are a March of Dimes' southeast Pennsylvania partner for their 2015 Prematurity Awareness Campaign. The program is designed to raise awareness of the urgency of the public health crisis of preterm birth and the ramifications of prematurity on infants and their families, and to thank healthcare professionals in neonatal intensive care units for their great efforts in caring for premature infants. Through this partnership, March of Dimes and Discovery Labs will share educational pieces for women of child bearing age in the five-county Philadelphia area to help educate mothers-to-be on prematurity and to foster awareness to help families have full-term, healthy babies.
DSCO: 1.43 (+0.05)
Discovery Laboratories' (DSCO) CEO John Cooper on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 10:12AM CST
DSCO: 1.43 (+0.05)
Discovery Laboratories posts 3Q loss
Automated Insights - Thu Nov 06, 9:12AM CST
WARRINGTON, Pa. (AP) _ Discovery Laboratories Inc. (DSCO) on Thursday reported a loss of $11.3 million in its third quarter.
DSCO: 1.43 (+0.05)
Discovery Laboratories beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:39AM CST
DSCO: 1.43 (+0.05)
Discovery Labs Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 6:30AM CST
Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the third quarter ended September 30, 2014, as well as recent business updates. The Company will host a conference call today, November 6, 2014 at 9:00 AM ET to discuss the 2014 third quarter financial results and other business updates.
DSCO: 1.43 (+0.05)
Discovery Labs Announces Organizational Change and Enhanced Expertise in Neonatology
PR Newswire - Thu Oct 30, 3:51PM CDT
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced organizational changes to the development leadership team and a special advisory appointment to augment the company's expertise in neonatology and aerosolized drug delivery.
DSCO: 1.43 (+0.05)
Discovery Labs to Report 2014 Third Quarter Financial Results and Hold Conference Call on Thursday, November 6, 2014 at 9:00 a.m. Eastern Time
PR Newswire - Wed Oct 29, 6:30AM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, will report its third quarter 2014 financial results on November 6, 2014 before the open of the U.S. financial markets.
DSCO: 1.43 (+0.05)
Discovery Laboratories: Collaboration With Battelle Is Validation Of Aerosurf's Potential By A Sophisticated Third Party
Smith On Stocks - at Seeking Alpha - Fri Oct 17, 7:16AM CDT
MNKD: 7.00 (+0.02), DSCO: 1.43 (+0.05)
Discovery Labs Announces Strategic Collaboration With Battelle For AEROSURF® Program
PR Newswire - Wed Oct 15, 6:30AM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it has entered into a strategic collaboration with Battelle, the world's largest independent research and development organization with 35 years of specific expertise in aerosol science. The parties intend to further develop Discovery Labs' proprietary capillary aerosol generator (CAG) for use in the planned AEROSURF® phase 3 clinical program and, if approved, initial commercialization. The arrangement also reflects the plan to negotiate agreements to provide for the manufacture of phase 3 clinical devices and, if AEROSURF is approved, initial commercial supply. The CAG is currently being used in neonatal intensive care units for the company's AEROSURF phase 2 clinical program for the treatment of respiratory distress syndrome (RDS) in premature infants. Battelle and Discovery Labs generally will share equally in the agreed costs of the device development for the AEROSURF RDS program. In consideration for its investment and expertise, Battelle will receive warrants and future royalties on AEROSURF sales and license sales revenues.
DSCO: 1.43 (+0.05)
Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury
PR Newswire - Wed Oct 01, 7:00AM CDT
Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that the Company has been awarded a Phase II Small Business Innovation Research Grant (SBIR) valued at up to $3.0 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of the Company's aerosolized KL4 surfactant as a medical countermeasure to mitigate acute and chronic/late-phase radiation-induced lung injury. The company has been awarded $1.0 million, and over the next three years may be awarded up to an additional $2.0 million as part of this grant. This program will be conducted in conjunction with Melpo Christofidou-Solomidou, Ph.D., a leading expert in novel antioxidant approaches to acute and chronic lung diseases from the University of Pennsylvania's Perelman School of Medicine. In fiscal year 2010, the Perelman School of Medicine received $583 million in support for its research activities from extramural sponsors, including $408 million from the National Institutes of Health, ranking third in the nation among all academic medical institutions.
DSCO: 1.43 (+0.05)
Your September Biotech Back-to-School Calendar
at The Street - Tue Aug 26, 8:50AM CDT
The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year.
OREX: 5.55 (+0.10), GILD: 101.90 (+1.10), CPRX: 3.36 (-0.10), ALIM: 5.16 (unch), AMRN: 1.18 (unch), ADHD: 6.92 (+0.73), SNSS: 2.28 (+0.01), NPSP: 45.88 (+0.03), LPCN: 5.91 (+0.40), DSCO: 1.43 (+0.05), XOMA: 3.41 (-0.01), KERX: 11.63 (-0.60)
Discovery Laboratories (DSCO) Worth Watching: Stock Up 6.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:25AM CDT
Discovery Laboratories (DSCO) was a big mover last session, with shares rising nearly 7% on the day.
HSKA: 20.95 (+0.07), GILD: 101.90 (+1.10), ILMN: 198.54 (+1.81), DSCO: 1.43 (+0.05)
